louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT02488798: Office Hysteroscopy and 3D Power Doppler Vaginal Ultrasound in Assessment of Postmenopausal Bleeding
Official title: The Role of Office Hysteroscopy and Endometrial Power Doppler Using the International Endometrial Tumor Analysis Group Classification in the Evaluation of Postmenopausal Bleeding
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Postmenopausal Bleeding
Lead sponsor: Cairo University
Sponsor class: OTHER
First posted: 2015-07-02
Enrollment: 100
Sex: FEMALE
Minimum age (years): 47
Maximum age (years): 64
Standard ages: ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Women with postmenopausal bleeding

Brief summary: 100 patients with postmenopausal bleeding were assessed with 2D vaginal ultrasound and 3D power Doppler ultrasound using the international endometrial tumor analysis group and office hysteroscopy with taking samples for histopathological analysis.

Detailed description: The aim was to compare the efficiency of the upper mentioned interventions in diagnosing the cause of postmenopausal bleeding.

Eligibility criteria: Inclusion Criteria:

* 100 patients complaining of postmenopausal bleeding. Postmenopausal bleeding was defined as vaginal bleeding that occurred after at least 12 months of amenorrhea.

Exclusion Criteria:

* Exclusion criteria included any history of hormone administration in the last 6 months, any medical condition that might cause abnormal uterine bleeding like coagulation disorders, hypertension, cardiac disease, thyroid disorders or hepatic condition.

Primary outcomes:
measure: Efficacy of 3D power Doppler ultrasound with the IETA group criteria in diagnosing the cause of postmenopausal bleeding
timeFrame: 1 week
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT00090298: Study to Evaluate the Cholesterol Lowering Effects of Two Marketed Drugs in Patients With Elevated Cholesterol Levels (0653A-058)
Official title: A Multicenter, Randomized, Double-Blind Study to Evaluate the Lipid-Altering Efficacy and Safety of the Ezetimibe/Simvastatin Combination Tablet Versus Rosuvastatin in Patients With Primary Hypercholesterolemia
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Hypercholesterolemia
Lead sponsor: Organon and Co
Sponsor class: INDUSTRY
First posted: 2004-08-30
Enrollment: 2815
Sex: ALL
Minimum age (years): 18
Maximum age (years): 69
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: A 10-week study to compare the reduction in cholesterol following treatment with two different marketed drugs in patients with hypercholesterolemia.

Detailed description: The duration of treatment is 6 weeks.

Eligibility criteria: Men and women aged 18 to 69 years, with elevated cholesterol levels may be eligible to participate in a research study to assess the efficacy and safety of two marketed drugs.

Primary outcomes:
measure: LDL-C lowering efficacy after 6 weeks.
Secondary outcomes:
measure: Safety;changes in TC, non-HDL-C, TG, HDL-C, Apo B, LDL-C/HCL-C ratio.
Other outcomes:
Locations:
Study officials:
affiliation: Merck Sharp & Dohme LLC
name: Medical Monitor
role: STUDY_DIRECTOR
References:
citation: Catapano AL, Davidson MH, Ballantyne CM, Brady WE, Gazzara RA, Tomassini JE, Tershakovec AM. Lipid-altering efficacy of the ezetimibe/simvastatin single tablet versus rosuvastatin in hypercholesterolemic patients. Curr Med Res Opin. 2006 Oct;22(10):2041-53. doi: 10.1185/030079906X132721.
Clinical trial NCT03355898: Acute Coronary Syndome With ST Elevation in Northern Lorraine
Official title: Acute Coronary Syndrome With ST Elevation in Northern Lorraine: Evolution of Clinicals, Epidemiological and Angiographic Data Since 2005
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Acute Coronary Syndrome
Lead sponsor: Centre Hospitalier Régional Metz-Thionville
Sponsor class: OTHER
First posted: 2017-11-28
Enrollment: 340
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: OTHER
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with an acute coronary syndrome with ST elevation in the CHR Metz-Thionville in 2005-2006, 2010-2011 and 2015

Brief summary: Lorraine is one of the most affected French region by cardiovascular diseases with a mortality rate for ischemic heart disease higher than the national average in 2010. Due to practice change with the new recommandations of the European Society of Cardiology involving the myocardic revascularization, the investigators wanted to compare the Stemi care in 2005-2006, 2010-2011 and 2015 in the CHR Metz-Thionville.

Detailed description: This monocentric study evaluate the impact of the new recommandations of the European Society of Cardiology in the acute coronary syndrome with ST elevation (Stemi) care. Data is compiled retrospectively from angiographic report and informatic medical record.

Eligibility criteria: Inclusion Criteria:

* Patient with an acute coronary syndrome with ST elevation for less than 12 hours
* Patients with coronarography in a context of cardiorespiratory arrest with unknown cause and acute coronary occlusion

Exclusion Criteria:

-

Primary outcomes:
measure: Acute coronary syndrome with ST elevation care
timeFrame: Day 1
Secondary outcomes:
measure: Stenting procedure
timeFrame: Day 1
measure: Hospital mortality
timeFrame: Day 1
measure: Epidemiology data
timeFrame: Day 1
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT03377998: Expression of Erythroid Differentiation Regulator 1 (Erdr1) in Vitiligo
Official title: Expression of Erythroid Differentiation Regulator 1 (Erdr1) Cytokine in the Vitiliginous Skin Lesions: a Case Control Study
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Erythroid Differentiation Regulator 1 (Erdr1) Cytokine
Lead sponsor: Cairo University
Sponsor class: OTHER
First posted: 2017-12-19
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: HEALTH_SERVICES_RESEARCH

Brief summary: Expression of Erythroid differentiation regulator 1 (Erdr1) cytokine in vitiligo


Eligibility criteria: Inclusion Criteria:

* Patients with generalized non-segmental vitiligo.
* Both sexes.
* Age \>18 years old.
* New cases or cases not receiving any medication for at least 3 months ago.

Exclusion Criteria:

* Segmental or Universal vitiligo
* Autoimmune diseases

Primary outcomes:
measure: Expression of tissue levels of erythroid differentiation regulator 1 (Erdr1) cytokine in patients of vitiligo
timeFrame: 6 months
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Cairo University
name: Maha Elmasry, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02462798: Does Sourdough Fermentation Improve Iron Uptake From Whole Grain Rye Bread?
Official title: Does Sourdough Fermentation Improve Iron Uptake From Whole Grain Rye Bread?
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Iron Bioavailability
Anaemia
Lead sponsor: Chalmers University of Technology
Sponsor class: OTHER
Collaborators: name: Sahlgrenska University Hospital
First posted: 2015-06-04
Enrollment: 102
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: BASIC_SCIENCE

Brief summary: Iron deficiency anaemia is a major problem for women worldwide. Cereal foods are a major source of iron, but much of this is not bioavailability due to it being bound by the high amounts of phytate present in cereals. Destruction of phytate by the phytase enzyme can release iron and increase its bioavailability. In a human cell model of iron uptake, sourdough fermentation, which included activation of phytase, the enzyme that breaks down phyate, led to improved iron bioavailability. This clinical trial will attempt to demonstrate that this concept also works in humans


Eligibility criteria: Inclusion Criteria:

* Healthy women under 50 years old

Exclusion Criteria:

* Pregnancy or breast feeding
* Use of mineral or other dietary supplements
* Use of medical or recreational drugs
* Donation of blood within the previous 3 months

Primary outcomes:
measure: Serum ferritin
timeFrame: 12 week values corrected for baseline
measure: Serum transferrin receptor
timeFrame: 12 week values corrected for baseline
measure: Haemoglobin
timeFrame: 12 week values corrected for baseline
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT04401098: Changing Of Egyptian Population Behaviour Towards COVID 19 Outbreak
Official title: Survey Of Egyptian Population Change in Knowledge, Attitude and Behaviour Towards COVID 19 Outbreak
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: COVID 19
Lead sponsor: Damanhour University
Sponsor class: OTHER
First posted: 2020-05-26
Enrollment: 700
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: OTHER
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: any individual of the Egyptian population of any age group.

Brief summary: During the COVID-19 pandemic, the Egyptian government issued movement restrictions and placed areas into quarantine to reduce the spread of the disease. In addition, individuals were encouraged to adopt personal protective measures, such as social isolation , increasing personal hygiene and wearing protective face masks. Information regarding the COVID 19 virus and protective measures is found on social media and ministry of health website and a number of the Egyptian population are keeping track of them .Public Awareness play a major rule in reducing the spread of COVID 19 so in this study a survey is done to measure the awareness of the Egyptian population toward COVID 19 , their knowledge and attitude and their adherence to preventive measures.It also measures the change of their behavior during the beginning of the outbreak and after a few months of the outbreak in Egypt.

Detailed description: Detailed Description:

The survey will enroll as many individuals of the Egyptian population as possible in the survey portion of the study - The number of participates have no limitations, at least 700 participants.

The survey will be enrolled in online google form, face to face interview(this will be reduced to encourage social isolation) \& semi-structured telephone interviews if possible.

The research procedures:

An online survey link will include questions regarding the awareness of the Egyptian population , their knowledge , attitudes and behaviour during covid-19 outbreak.and also a comparison of their behaviour among different time periods of the outbreak Face to face and semi-structured interviews if possible: For those Egyptian citizens who state that they would like to participate in an interview, a random sample will be contacted.

Inclusion Criteria:

Egyptian population of any age group

Exclusion Criteria:

none

Eligibility criteria: Inclusion Criteria:

Egyptian population of different age groups

Exclusion Criteria:

none

Primary outcomes:
measure: awareness of Egyptian population
timeFrame: 6 months
Secondary outcomes:
Other outcomes:
Locations:
city: Damanhūr
country: Egypt
facility: Damanhour University
state: Beheira
Study officials:
References:
Clinical trial NCT02636998: Nutrition and Cognitive Function in Preadolescents
Official title: Nutrition and Cognitive Function in Preadolescents
Study type: OBSERVATIONAL
Overall status: ACTIVE_NOT_RECRUITING
Conditions: Healthy Children
Lead sponsor: Arkansas Children's Hospital Research Institute
Sponsor class: OTHER
First posted: 2015-12-22
Enrollment: 116
Sex: ALL
Minimum age (years): 9
Maximum age (years): 11
Standard ages: CHILD
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Preadolescents and their mothers

Brief summary: This study is designed to evaluate cognitive function in preadolescents who have different body mass indexes.

Detailed description: The investigators plan to document differences between normal weight and obese preadolescents on psychological and neurocognitive measures of executive function controlling for factors known to influence brain function and behavior not considered in previous studies.

Eligibility criteria: Inclusion Criteria:

* Normal weight (BMI: \<85th percentile) or obese (BMI: \>95th percentile)
* Right hand dominance
* Report eating breakfast at least 4 days/week
* Able to hear at least 20 dB stimulus
* Visual acuity must be at least 20/40
* Arithmetic Computation Task
* Biological mother available to attend the enrollment study visit

Exclusion Criteria:

* Full Scale IQ \<80
* Children taking medications or having chronic illnesses/disorders that may independently affect study outcome measures (as determined by the PI)

Primary outcomes:
measure: Psychological assessments
timeFrame: 9-10 years
measure: Neurocognitive measures
timeFrame: 9-10 years
Secondary outcomes:
Other outcomes:
Locations:
city: Little Rock
country: United States
facility: Arkansas Children's Nutrition Center
state: Arkansas
Study officials:
affiliation: Arkansas Children's Nutrition Center
name: Linda Larson-Prior, Ph.D
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00921245: FREEDOM - First Real-Life Evaluation of Enablex Done in ZA Overactive Bladder Patients During a 3 Months Period
Official title: First REal-life Evaluation of Darifenacin in Overactive Bladder Patients During 3 Months
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Overactive Bladder
Keywords: Overactive Bladder
Lead sponsor: Bayer
Sponsor class: INDUSTRY
First posted: 2009-06-16
Enrollment: 9
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Private Practice Patients

Brief summary: Patient perspective on Overactive Bladder and symptoms experienced after administration of Darifenacin


Eligibility criteria: Inclusion Criteria:

* Male and female patients \> 18 years with symptoms of overactive bladder.

Exclusion Criteria:

* Contraindications for the treatment with Darifenacin prolonged-release tablets according to the registered package insert.
* Pregnancy and lactation. Women of childbearing potential have to use an acceptable method of contraception.
* Concomitant treatment with drugs known to affect mainly the urinary bladder function (e.g. anticholinergics, antispasmodics) at any time during the study. Concomitant treatment with botulinum toxin, capsaicin or resiniferatoxin at any time during the study and treatment with botulinum toxin, capsaicin or resiniferatoxin in the last 6 months prior to Visit 1.

Primary outcomes:
measure: To evaluate safety and tolerability of Darifenacin in the daily practice for the treatment of the OAB (Over Active Bladder) syndrome.
timeFrame: 3 months later
Secondary outcomes:
measure: To evaluate the patient's perception of bladder condition, the patient's use of the patient support program, the patient's and physician's assessment of treatment regarding efficacy and tolerability and patient's compliance with the treatment
timeFrame: 3 months later
Other outcomes:
Locations:
city: Many Locations
country: South Africa
Study officials:
affiliation: Bayer
name: Bayer Study Director
role: STUDY_DIRECTOR
References:
Clinical trial NCT00752245: Uremic Toxins in the Intensive Care Unit (ICU): Patients With Sepsis
Official title: Study of the Kinetics of Uremic Toxins in the ICU Patients With Acute Renal Failure, in Order to Optimize the Dialysis Dose: Patients With Sepsis/Multi-organ Failure
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: NA
Conditions: Renal Failure
Multi Organ Failure
Keywords: ICU patients with acute renal failure with sepsis/multi-organ failure
Lead sponsor: University Hospital, Ghent
Sponsor class: OTHER
First posted: 2008-09-15
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: Study of the kinetics of uremic toxins in the ICU patients with acute renal failure, in order to optimize the dialysis dose: patients with sepsis/multi-organ failure. The sampling of blood and dialysate will be done during dialyses with different durations (4, 6 and 8h)


Eligibility criteria: Inclusion Criteria:

* ICU patients with sepsis/multi-organ failure with acute renal failure

Primary outcomes:
measure: Registration of toxin removal efficiency
timeFrame: During dialysis
Secondary outcomes:
Other outcomes:
Locations:
city: Ghent
country: Belgium
facility: University Hospital Ghent
Study officials:
affiliation: University Hospital, Ghent
name: Raymond Vanholder, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06923098: PET/CT GUIDED BIOPSY VERSUS CT GUIDED BIOPSY IN EVALUATION OF SUSPECTED LUNG NEOPLASMS
Official title: PET/CT GUIDED BIOPSY VERSUS CT GUIDED BIOPSY IN EVALUATION OF SUSPECTED LUNG NEOPLASMS
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Lung Diseases
Keywords: CT guided biopsy
PET-CT guided biopsy
Lung lesions
Lead sponsor: All India Institute of Medical Sciences, Bhubaneswar
Sponsor class: OTHER
First posted: 2025-04-11
Enrollment: 108
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: DIAGNOSTIC

Brief summary: Percutaneous CT guided biopsy is a well-established, standard sampling technique for suspected neoplastic lesions located in peripheral region in lung parenchyma. Inconclusive results on CT guided biopsy is substantially higher in large lung lesions which are prone to cause peripheral pneumonia, atelectasis and even regional necrosis, which are hard to be distinguished from tumor on CT images.

Functional imaging guided biopsy like PET/CT guided biopsy identifies areas of highest concentration of neoplastic cells and provides accurate results. Only a few studies have been done regarding PET/CT guided biopsy and studies omparing PET/CT guided and CT guided percutaneous transthoracic lung biopsy are very few and this study would be a randomized trial comparing these diagnostic modalities in terms of diagnostic yield, diagnostic accuracy of sample and complications.


Eligibility criteria: Inclusion Criteria:

* Age above 18 years
* INR \&lt; 1.2 and platelet counts \&gt; 80,000/mm3
* CT thorax with lung lesion more than 10 mm.
* Accessible lesions for CT-guided biopsy.

Exclusion Criteria:

* Participants with pre-existing bleeding diathesis like hemophilia, coagulopathy defined by -INR ≥1.2 and Platelet counts ≤ 80,000/mm3
* Participants who refuse to provide consent
* Signs of hypoperfusion like hypotension, cyanosis etc.
* Presence of hypoxemia with SpO2 \< 94 %- measured in a pulse oximeter)
* Pregnant/Lactating female subjects
* Non-cooperative subjects
* Lesions that are inaccessible (decision made on pre-biopsy planning)
* Serum creatinine level more than 2mg/dl.

Primary outcomes:
measure: Inconclusive pathology findings
timeFrame: 1 month
Secondary outcomes:
measure: Incidence of pneumothorax and hemoptysis
timeFrame: 1 month
Other outcomes:
Locations:
city: Bhubaneswar
country: India
facility: All India Institute of Medical Sciences, Bhubaneswar
state: Odisha
Study officials:
References:
Clinical trial NCT03806998: Effects of a Ketoacid Supplementation in Patients With Stage III to IV Renal Failure
Official title: Effects of a Ketoacid Supplementation on Urinary Urea Nitrogen Excretion in Patients With Stage III to IV Renal Failure
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Renal Failure
Lead sponsor: University of Chile
Sponsor class: OTHER
Collaborators: name: Servicio de Salud Metropolitano Oriente
First posted: 2019-01-16
Enrollment: 147
Sex: ALL
Minimum age (years): 40
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Participants will be randomly assgned to receive the ketoacid supplement or placebo
Primary purpose: TREATMENT

Brief summary: The aim of the study is to demonstrate that a ketoacid supplement in patients with stage III to IV chronic renal failure, reduces the excretion of urinary urea nitrogen

Detailed description: Patients with an estimated glomerular filtration rate of less than 25 ml/kg/min, not on renal substitution therapy, without important concomitant diseases and aged between 40 and 70 years, will be invited to participate in the study. They will be randomly assigned to a group that will receive receive a supplement of ketoacids (Ketosteril) 1 tablet containing 630 mg of ketoacids every 5 kg of body weight and a diet containing 25 to 35 kcal/kg and 0.3 g/protein per day or to a group receiving placebo and a diet containing 25 to 35 kcal/kg and 0.6 g/protein per day. The intervention will last 16 weeks. At baseline and the end of the intervention a blood sample will be obtained to measure creatinine, urea nitrogen and cystatin C. Also a spot urine sample will be obtained to measure urea nitrogen and creatinine excretion. The compliance with the dietary prescription and the ketoacid or placebo supplement will be assessed every 2 weeks.

Eligibility criteria: Inclusion Criteria:

* Estimated glomerular filtration rate of less tan 25/ml/min/1.73m2
* Not on renal substitution therapy
* Absence of severe life threatening concomitant diseases

Exclusion Criteria:

* Malignant or renovascular hypertension
* Use of systemic steroids or immunosuppressant drugs
* Alcohol or illicit drug abuse
* A body mass index of less tan 18 kg/m2

Primary outcomes:
measure: Estimated glomerular filtration rate
timeFrame: 16 weeks
measure: Urinary urea nitrogen excretion
timeFrame: 16 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Santiago
country: Chile
facility: Hospital del Salvador
state: Metropolitana
Study officials:
affiliation: INTA University of Chile
name: Daniel Bunout, MD
role: PRINCIPAL_INVESTIGATOR
References: